Literature DB >> 25410752

MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4).

Jing Xue1, Li-Zhang Chen, Zhan-Zhan Li, Ying-yun Hu, Shi-peng Yan, Li-Ya Liu.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. P21-activated kinase 4 (PAK4) has been identified as an oncogenic protein in a variety of cancers. However, the contribution and regulation of PAK4 in HCC remain poorly understood. In the present study, we found that inhibition of PAK4 expression by specific shRNA significantly attenuated HCC cell proliferation. Moreover, we show that microRNA-433 (miRNA-433) could directly target PAK4 through the miRNA-433 binding sequence at the 3'-UTR of PAK4 mRNA, and inhibit PAK4 protein expression. We further show that miRNA-433 expression was downregulated in HCC tissues and cell culture as well, which inversely correlated with PAK4 expression levels. Overexpression of miRNA-433 significantly suppressed the proliferation of HepG2 cells, while this effect was partially rescued by forced expression of PAK4 through restoring PI3K/AKT signaling in HepG2 cells. These findings will shed light on the roles and mechanisms of miRNA-433 in regulating HCC proliferation, and may benefit future development of therapeutics targeting miRNA-433 and PAK4 in HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25410752     DOI: 10.1007/s11010-014-2234-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  29 in total

Review 1.  MicroRNAs: synthesis, mechanism, function, and recent clinical trials.

Authors:  Fazli Wahid; Adeeb Shehzad; Taous Khan; You Young Kim
Journal:  Biochim Biophys Acta       Date:  2010-07-07

2.  MicroRNA-133a regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis.

Authors:  Song Gao; Michael Wassler; Lulu Zhang; Yangxin Li; Jun Wang; Yi Zhang; Harnath Shelat; Jason Williams; Yong-Jian Geng
Journal:  Atherosclerosis       Date:  2013-11-19       Impact factor: 5.162

3.  miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.

Authors:  X Lin; K L Rice; M Buzzai; E Hexner; F F Costa; O Kilpivaara; A Mullally; M B Soares; B L Ebert; R Levine; J D Licht
Journal:  Leukemia       Date:  2012-08-06       Impact factor: 11.528

4.  LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.

Authors:  Jian Zhang; Jian Wang; Qiqiang Guo; Yu Wang; Ying Zhou; Huizhi Peng; Maosheng Cheng; Dongmei Zhao; Feng Li
Journal:  Cancer Lett       Date:  2011-11-13       Impact factor: 8.679

5.  A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF.

Authors:  Tasneem Ahmed; Kerry Shea; John R W Masters; Gareth E Jones; Claire M Wells
Journal:  Cell Signal       Date:  2008-03-12       Impact factor: 4.315

6.  HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity.

Authors:  Gang Ding; He-Dai Liu; Qian Huang; Hong-Xiang Liang; Zhao-Han Ding; Zhi-Jun Liao; Gang Huang
Journal:  FEBS Lett       Date:  2013-02-10       Impact factor: 4.124

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 8.  MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death.

Authors:  R Schickel; B Boyerinas; S-M Park; M E Peter
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

9.  PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.

Authors:  Xueqiong Fu; Jiarui Feng; Duan Zeng; Yu Ding; Changshou Yu; Bing Yang
Journal:  Biosci Rep       Date:  2014-04-01       Impact factor: 3.840

10.  Identification of GRB2 and GAB1 coexpression as an unfavorable prognostic factor for hepatocellular carcinoma by a combination of expression profile and network analysis.

Authors:  Yanqiong Zhang; Zhiwei Li; Mei Yang; Danhua Wang; Lingxiang Yu; Chaonan Guo; Xiaodong Guo; Na Lin
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

View more
  12 in total

Review 1.  Structure, biochemistry, and biology of PAK kinases.

Authors:  Rakesh Kumar; Rahul Sanawar; Xiaodong Li; Feng Li
Journal:  Gene       Date:  2016-12-19       Impact factor: 3.688

2.  Expression level of miRNAs on chromosome 14q32.31 region correlates with tumor aggressiveness and survival of glioblastoma patients.

Authors:  Tal Shahar; Avital Granit; Daniel Zrihan; Tamar Canello; Hanna Charbit; Ofira Einstein; Uri Rozovski; Sharona Elgavish; Zvi Ram; Tali Siegal; Iris Lavon
Journal:  J Neurooncol       Date:  2016-08-29       Impact factor: 4.130

Review 3.  p21-Activated kinases as promising therapeutic targets in hematological malignancies.

Authors:  Andrew Wu; Xiaoyan Jiang
Journal:  Leukemia       Date:  2021-10-25       Impact factor: 11.528

4.  Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4.

Authors:  Zhiheng Li; Xiaolu Li; Lixiao Xu; Yanfang Tao; Chun Yang; Xiaolan Chen; Fang Fang; Yi Wu; Xin Ding; He Zhao; Mei Li; Guanghui Qian; Yunyun Xu; Junli Ren; Weiwei Du; Jian Wang; Jun Lu; Shaoyan Hu; Jian Pan
Journal:  Oncol Rep       Date:  2017-09-22       Impact factor: 3.906

5.  The construction and analysis of ceRNA networks in invasive breast cancer: a study based on The Cancer Genome Atlas.

Authors:  Chundi Gao; Huayao Li; Jing Zhuang; HongXiu Zhang; Kejia Wang; Jing Yang; Cun Liu; Lijuan Liu; Chao Zhou; Changgang Sun
Journal:  Cancer Manag Res       Date:  2018-12-17       Impact factor: 3.989

6.  PAK4, a target of miR-9-5p, promotes cell proliferation and inhibits apoptosis in colorectal cancer.

Authors:  Meihua Wang; Qianqian Gao; Yufang Chen; Ziyan Li; Lingping Yue; Yun Cao
Journal:  Cell Mol Biol Lett       Date:  2019-11-08       Impact factor: 5.787

7.  MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4.

Authors:  Zhenhua Wu; Jie Geng; Yujuan Qi; Jian Li; Yaobang Bai; Zhigang Guo
Journal:  Pulm Circ       Date:  2020-12-10       Impact factor: 3.017

8.  MicroRNA-433 inhibits oral squamous cell carcinoma cells by targeting FAK.

Authors:  Yong-Jian Wang; Zi-Feng Zhang; Shao-Hua Fan; Juan Zhuang; Qun Shan; Xin-Rui Han; Xin Wen; Meng-Qiu Li; Bin Hu; Chun-Hui Sun; Bin Qiao; Qian Tao; Dong-Mei Wu; Jun Lu; Yuan-Lin Zheng
Journal:  Oncotarget       Date:  2017-10-27

9.  Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma.

Authors:  Jun Fu; Yanyan Li; Zhanzhan Li; Na Li
Journal:  Biosci Rep       Date:  2018-10-05       Impact factor: 3.840

10.  miR-433 inhibits breast cancer cell growth via the MAPK signaling pathway by targeting Rap1a.

Authors:  Tao Zhang; Kangfeng Jiang; Xinying Zhu; Gan Zhao; Haichong Wu; Ganzhen Deng; Changwei Qiu
Journal:  Int J Biol Sci       Date:  2018-05-15       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.